Fresenius SE & Co KGaA
XETRA:FRE
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
35.17
51.98
|
| Price Target |
|
We'll email you a reminder when the closing price reaches EUR.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Operating Margin
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Peer Comparison
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| DE |
|
Fresenius SE & Co KGaA
XETRA:FRE
|
27.4B EUR |
Loading...
|
|
| US |
|
CVS Health Corp
NYSE:CVS
|
105.6B USD |
Loading...
|
|
| US |
C
|
Cigna Group
XMUN:CGN
|
63B EUR |
Loading...
|
|
| US |
|
Cigna Corp
NYSE:CI
|
74.7B USD |
Loading...
|
|
| DE |
|
Fresenius Medical Care AG
XMUN:FME
|
21.9B EUR |
Loading...
|
|
| US |
|
Laboratory Corporation of America Holdings
NYSE:LH
|
22.1B USD |
Loading...
|
|
| US |
|
Quest Diagnostics Inc
NYSE:DGX
|
20.2B USD |
Loading...
|
|
| US |
|
Guardant Health Inc
NASDAQ:GH
|
14.5B USD |
Loading...
|
|
| DE |
F
|
Fresenius Medical Care AG & Co KGaA
XETRA:FME
|
10.8B EUR |
Loading...
|
|
| AU |
|
Sonic Healthcare Ltd
ASX:SHL
|
11.1B AUD |
Loading...
|
|
| US |
|
DaVita Inc
NYSE:DVA
|
7.6B USD |
Loading...
|
Market Distribution
| Min | -61 459.6% |
| 30th Percentile | 0.7% |
| Median | 4.5% |
| 70th Percentile | 9.8% |
| Max | 94 540% |
Other Profitability Ratios
Fresenius SE & Co KGaA
Glance View
Fresenius SE & Co. KGaA, a titan in the global healthcare sector, traces its origins to a humble pharmacy in Frankfurt, Germany, in 1912. Since then, the company has evolved into a multifaceted healthcare conglomerate, positioning itself prominently in four main divisions: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. Each segment synergizes to form a comprehensive healthcare ecosystem. Fresenius Medical Care, the crown jewel of the group, stands as the world’s leading provider of products and services for individuals with renal diseases. This division, with a focus on dialyzing patients suffering from chronic kidney failure, operates a vast network of dialysis clinics and manufactures dialysis machines and related products that account for a significant portion of its income. Meanwhile, Fresenius Kabi, the pharmaceutical and medical device division, specializes in lifesaving drugs and technologies for critically and chronically ill patients. This division thrives on providing clinical nutrition, infusion therapy, and generics, positioning itself as a critical player in hospitals worldwide. Fresenius Helios is acknowledged as Europe's largest private hospital operator, managing a vast array of healthcare facilities that deliver inpatient and outpatient care, ensuring a steady stream of revenue through diverse healthcare services. Lastly, Fresenius Vamed provides a wide range of services for healthcare facilities, from project development and construction to full operational management, allowing the company to gain financial benefits from turnkey hospital solutions and infrastructure development. Through these concerted efforts, Fresenius SE & Co. KGaA cements its role as a key stakeholder in the global healthcare market, generating substantial revenues while addressing diverse medical needs across the globe.
See Also
Operating Margin is calculated by dividing the Operating Income by the Revenue.
The current Operating Margin for Fresenius SE & Co KGaA is 9.8%, which is above its 3-year median of 7.6%.
Over the last 3 years, Fresenius SE & Co KGaA’s Operating Margin has increased from 9.4% to 9.8%. During this period, it reached a low of 5.7% on Jun 30, 2024 and a high of 9.9% on Jun 30, 2025.